LivaNova PLC (NASDAQ:LIVN) Stock Holdings Decreased by Twinbeech Capital LP

Twinbeech Capital LP lowered its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 91.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 5,204 shares of the company's stock after selling 54,091 shares during the quarter. Twinbeech Capital LP's holdings in LivaNova were worth $241,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. KBC Group NV boosted its stake in LivaNova by 130.5% during the 4th quarter. KBC Group NV now owns 99,928 shares of the company's stock valued at $4,628,000 after purchasing an additional 56,580 shares during the period. Rhumbline Advisers raised its holdings in shares of LivaNova by 0.5% during the fourth quarter. Rhumbline Advisers now owns 177,938 shares of the company's stock valued at $8,240,000 after buying an additional 899 shares during the last quarter. Principal Financial Group Inc. boosted its position in shares of LivaNova by 2.6% during the fourth quarter. Principal Financial Group Inc. now owns 175,878 shares of the company's stock worth $8,145,000 after buying an additional 4,476 shares during the period. Paradice Investment Management LLC boosted its position in shares of LivaNova by 15.3% during the fourth quarter. Paradice Investment Management LLC now owns 486,821 shares of the company's stock worth $22,545,000 after buying an additional 64,680 shares during the period. Finally, New York State Common Retirement Fund grew its holdings in LivaNova by 122.8% in the 4th quarter. New York State Common Retirement Fund now owns 37,557 shares of the company's stock worth $1,739,000 after buying an additional 20,699 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

LivaNova Price Performance

Shares of LivaNova stock traded down $1.23 during trading on Wednesday, hitting $42.79. The stock had a trading volume of 513,412 shares, compared to its average volume of 651,185. The business has a fifty day moving average of $38.86 and a two-hundred day moving average of $44.48. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $61.94. The firm has a market cap of $2.33 billion, a P/E ratio of 101.88 and a beta of 0.84. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87.

Analyst Ratings Changes

Several analysts have weighed in on LIVN shares. Robert W. Baird lifted their target price on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Needham & Company LLC restated a "buy" rating and set a $64.00 price objective on shares of LivaNova in a research note on Tuesday, May 13th. Stifel Nicolaus reduced their price objective on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Wall Street Zen lowered shares of LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, The Goldman Sachs Group dropped their price target on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $59.29.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.